CorMedix (CRMD)
CorMedix on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
14.7M
Short interest
settlement 2026-10-15
12.7
Days to cover
-6.2 days vs prior
70.0%
Short share of volume
2026-11-03
3,210
Fails to deliver
settlement 2026-09-18
Thu 7 Jan
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in CRMD is 14,665,697 shares, down 1,536,575 shares over the last month. Over the last 48 readings it ranged from 6,284,633 shares (31 October 2024) to 17,892,607 shares (15 January 2026). At the reported average volume of 1.2M shares a day that is 12.7 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/crmd" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 14,665,697 | -4.9% | 1,157,960 | 12.67 |
| 2026-09-30 | 15,422,728 | -4.8% | 815,972 | 18.90 |
| 2026-09-15 | 16,202,272 | +1.1% | 876,181 | 18.49 |
| 2026-08-31 | 16,032,112 | -6.5% | 1,235,123 | 12.98 |
| 2026-08-14 | 17,149,908 | +5.3% | 1,551,888 | 11.05 |
| 2026-07-31 | 16,283,087 | +6.1% | 952,180 | 17.10 |
| 2026-07-15 | 15,349,811 | +2.8% | 902,354 | 17.01 |
| 2026-06-30 | 14,930,822 | +2.9% | 1,926,289 | 7.75 |
| 2026-06-15 | 14,505,152 | -0.3% | 1,218,061 | 11.91 |
| 2026-05-29 | 14,551,054 | -6.4% | 1,332,674 | 10.92 |
| 2026-05-15 | 15,541,297 | -4.2% | 1,456,573 | 10.67 |
| 2026-04-30 | 16,222,947 | +3.2% | 974,883 | 16.64 |
| 2026-04-15 | 15,719,495 | -0.4% | 989,286 | 15.89 |
| 2026-03-31 | 15,782,505 | -0.4% | 1,322,903 | 11.93 |
| 2026-03-13 | 15,846,435 | -4.6% | 1,998,683 | 7.93 |
| 2026-02-27 | 16,618,186 | -1.6% | 1,142,037 | 14.55 |
| 2026-02-13 | 16,896,431 | +3.4% | 1,952,033 | 8.66 |
| 2026-01-30 | 16,339,585 | -8.7% | 2,561,521 | 6.38 |
| 2026-01-15 | 17,892,607 | +7.1% | 5,708,710 | 3.13 |
| 2025-12-31 | 16,701,569 | -1.0% | 2,276,133 | 7.34 |
| 2025-12-15 | 16,875,402 | -1.2% | 3,061,579 | 5.51 |
| 2025-11-28 | 17,080,635 | -2.1% | 2,727,015 | 6.26 |
| 2025-11-14 | 17,445,325 | +5.1% | 3,523,039 | 4.95 |
| 2025-10-31 | 16,599,216 | +2.6% | 2,738,866 | 6.06 |
| 2025-10-15 | 16,179,795 | +4.0% | 2,005,469 | 8.07 |
| 2025-09-30 | 15,564,623 | -6.6% | 2,915,163 | 5.34 |
| 2025-09-15 | 16,671,740 | +40.3% | 6,039,773 | 2.76 |
| 2025-08-29 | 11,886,496 | -16.2% | 3,073,197 | 3.87 |
| 2025-08-15 | 14,179,171 | +32.8% | 3,989,937 | 3.55 |
| 2025-07-31 | 10,679,715 | +6.3% | 2,113,702 | 5.05 |
| 2025-07-15 | 10,049,276 | +4.1% | 1,516,465 | 6.63 |
| 2025-06-30 | 9,650,210 | +12.4% | 2,998,540 | 3.22 |
| 2025-06-13 | 8,588,351 | +0.6% | 1,741,586 | 4.93 |
| 2025-05-30 | 8,533,637 | +1.0% | 1,146,524 | 7.44 |
| 2025-05-15 | 8,450,282 | +5.1% | 3,045,436 | 2.77 |
| 2025-04-30 | 8,043,655 | -2.6% | 1,237,882 | 6.50 |
| 2025-04-15 | 8,256,042 | +4.2% | 1,522,560 | 5.42 |
| 2025-03-31 | 7,924,601 | -3.1% | 3,115,499 | 2.54 |
| 2025-03-14 | 8,179,030 | +3.8% | 753,814 | 10.85 |
| 2025-02-28 | 7,876,541 | +6.6% | 872,715 | 9.03 |
| 2025-02-14 | 7,388,311 | +2.9% | 631,549 | 11.70 |
| 2025-01-31 | 7,177,892 | +1.3% | 1,322,180 | 5.43 |
| 2025-01-15 | 7,083,149 | +1.1% | 1,672,839 | 4.23 |
| 2024-12-31 | 7,002,343 | +4.1% | 898,722 | 7.79 |
| 2024-12-13 | 6,728,207 | -2.4% | 845,740 | 7.96 |
| 2024-11-29 | 6,891,533 | +0.8% | 940,918 | 7.32 |
| 2024-11-15 | 6,840,218 | +8.8% | 1,268,857 | 5.39 |
| 2024-10-31 | 6,284,633 | -20.1% | 1,777,574 | 3.54 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of CRMD volume is 70.0%, down 1.2 points over the last five sessions. Over the last 30 readings it ranged from 32.7% (12 October 2026) to 79.7% (29 October 2026). The latest reading is 11.8 points above the 30-session average of 58.2%, on 912K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 639K | 912K | 70.0% | 224 |
| 2026-11-02 | 664K | 1.2M | 55.5% | 48,041 |
| 2026-10-30 | 2.5M | 3.4M | 73.6% | 201,435 |
| 2026-10-29 | 664K | 833K | 79.7% | 0 |
| 2026-10-28 | 273K | 498K | 54.8% | 400 |
| 2026-10-27 | 248K | 348K | 71.2% | 0 |
| 2026-10-26 | 359K | 477K | 75.2% | 1,317 |
| 2026-10-23 | 276K | 412K | 67.0% | 200 |
| 2026-10-22 | 175K | 402K | 43.4% | 506 |
| 2026-10-21 | 184K | 318K | 57.8% | 181 |
| 2026-10-20 | 171K | 353K | 48.6% | 52 |
| 2026-10-19 | 400K | 650K | 61.6% | 1,666 |
| 2026-10-16 | 309K | 457K | 67.5% | 70 |
| 2026-10-15 | 284K | 512K | 55.5% | 31 |
| 2026-10-14 | 254K | 476K | 53.3% | 946 |
| 2026-10-13 | 218K | 567K | 38.5% | 1,224 |
| 2026-10-12 | 253K | 775K | 32.7% | 450 |
| 2026-10-09 | 162K | 404K | 40.1% | 1,500 |
| 2026-10-08 | 146K | 274K | 53.1% | 1,000 |
| 2026-10-07 | 162K | 286K | 56.6% | 443 |
| 2026-10-06 | 197K | 287K | 68.8% | 1 |
| 2026-10-05 | 294K | 500K | 58.8% | 8,088 |
| 2026-10-02 | 295K | 454K | 64.8% | 5,602 |
| 2026-10-01 | 235K | 330K | 71.3% | 4,819 |
| 2026-09-30 | 179K | 343K | 52.2% | 765 |
| 2026-09-29 | 120K | 311K | 38.6% | 27 |
| 2026-09-28 | 114K | 186K | 61.3% | 3,057 |
| 2026-09-25 | 113K | 205K | 55.1% | 3,313 |
| 2026-09-24 | 142K | 285K | 49.9% | 1 |
| 2026-09-23 | 218K | 317K | 68.9% | 1,081 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 18 September 2026, the fails-to-deliver balance in CRMD is 3,210 shares, down 21,480 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (8 September 2026) to 285,002 shares (30 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-18 | 3,210 | $7.79 | $25K |
| 2026-09-16 | 24,690 | $7.76 | $192K |
| 2026-09-10 | 1,040 | $8.13 | $8K |
| 2026-09-08 | 4 | $8.43 | $34 |
| 2026-09-04 | 2,072 | $8.47 | $18K |
| 2026-08-26 | 1,000 | $8.56 | $9K |
| 2026-08-24 | 42 | $8.20 | $344 |
| 2026-08-17 | 22,204 | $7.54 | $167K |
| 2026-08-11 | 675 | $7.53 | $5K |
| 2026-07-31 | 78,079 | $7.49 | $585K |
| 2026-07-30 | 285,002 | $7.19 | $2.0M |
| 2026-07-29 | 3,816 | $7.35 | $28K |
| 2026-07-21 | 12,006 | $7.78 | $93K |
| 2026-07-20 | 2,198 | $8.42 | $19K |
| 2026-07-17 | 9,023 | $8.29 | $75K |
| 2026-07-16 | 10,440 | $8.42 | $88K |
| 2026-07-13 | 6,032 | $8.40 | $51K |
| 2026-07-09 | 1,099 | $8.83 | $10K |
| 2026-07-07 | 15,930 | $8.79 | $140K |
| 2026-07-06 | 11,896 | $8.75 | $104K |
| 2026-07-02 | 7,389 | $8.47 | $63K |
| 2026-07-01 | 28,196 | $7.85 | $221K |
| 2026-06-29 | 13,022 | $7.85 | $102K |
| 2026-06-25 | 205,760 | $8.39 | $1.7M |
| 2026-06-23 | 4,305 | $8.82 | $38K |
| 2026-06-22 | 2,000 | $8.67 | $17K |
| 2026-06-18 | 55 | $8.67 | $477 |
| 2026-06-15 | 18,642 | $8.74 | $163K |
| 2026-06-12 | 15,603 | $8.96 | $140K |
| 2026-06-09 | 1,956 | $8.54 | $17K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for CRMD in the last 90 days. The most recent filings are listed below. Latest filing: Dillione Janet (Director) on 2026-09-18.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-18 | Dillione Janet | Director | Exercise or conversion | 49K | price not stated in the filing | not stated | 118K |
| 2026-08-29 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 8K | $8.30 | $67K | 270K |
| 2026-08-29 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 8K | $8.30 | $70K | 261K |
| 2026-08-29 | Blum Susan | Chief Financial Officer | Tax withholding | 8K | $8.30 | $70K | 124K |
| 2026-02-04 | Zelnick Kaufman Beth | Chief Legal Officer | Grant | 36K | $0.00 | $0 | 269K |
| 2026-02-04 | Hurlburt Elizabeth | Chief Operating Officer | Grant | 36K | $0.00 | $0 | 279K |
| 2026-02-04 | Todisco Joseph | Chief Executive Officer | Grant | 77K | $0.00 | $0 | 775K |
| 2026-01-26 | Stewart Robert A | Director | Grant | 30K | $0.00 | $0 | 66K |
| 2026-01-26 | Dillione Janet | Director | Grant | 30K | $0.00 | $0 | 69K |
| 2026-01-26 | DUNTON ALAN W | Director | Grant | 30K | $0.00 | $0 | 71K |
| 2026-01-26 | Lefkowitz Steven W | Director | Grant | 30K | $0.00 | $0 | 126K |
| 2026-01-26 | Kaplan Myron | Director | Grant | 30K | $0.00 | $0 | 231K |
| 2026-01-26 | Duncan Gregory Scott | Director | Grant | 30K | $0.00 | $0 | 69K |
| 2026-01-23 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 9K | $7.27 | $64K | 233K |
| 2026-01-23 | Zelnick Kaufman Beth | Chief Legal Officer | Grant | 73K | $0.00 | $0 | 242K |
| 2026-01-23 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 11K | $7.27 | $78K | 243K |
| 2026-01-23 | Hurlburt Elizabeth | Chief Operating Officer | Grant | 93K | $0.00 | $0 | 253K |
| 2026-01-23 | Todisco Joseph | Chief Executive Officer | Tax withholding | 27K | $7.27 | $199K | 698K |
| 2026-01-23 | Todisco Joseph | Chief Executive Officer | Grant | 226K | $0.00 | $0 | 725K |
| 2026-01-23 | Blum Susan | Chief Financial Officer | Tax withholding | 10K | $7.27 | $71K | 133K |
| 2026-01-23 | Blum Susan | Chief Financial Officer | Grant | 73K | $0.00 | $0 | 143K |
| 2026-01-21 | Dillione Janet | Director | Sell | 10K | $6.88 | $69K | 38K |
| 2026-01-17 | Todisco Joseph | Chief Executive Officer | Tax withholding | 23K | $6.78 | $154K | 499K |
| 2026-01-16 | Todisco Joseph | Chief Executive Officer | Exercise or conversion | 30K | $3.38 | $100K | 522K |
| 2026-01-12 | Lefkowitz Steven W | Director | Exercise or conversion | 15K | $5.63 | $84K | 95K |
| 2026-01-12 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 6K | $7.15 | $41K | 160K |
| 2026-01-12 | Todisco Joseph | Chief Executive Officer | Tax withholding | 17K | $7.15 | $125K | 492K |
| 2026-01-08 | Seckler Michael David | Chief Commercial Officer | Grant | 133K | $0.00 | $0 | 133K |
| 2026-01-02 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 11K | $12.16 | $132K | 166K |
| 2026-01-02 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 11K | $12.16 | $138K | 169K |
| 2025-12-30 | DUNTON ALAN W | Director | Sell | 20K | $13.00 | $260K | 40K |
| 2025-12-30 | DUNTON ALAN W | Director | Exercise or conversion | 20K | $4.03 | $81K | 60K |
| 2025-12-18 | Todisco Joseph | Chief Executive Officer | Sell | 30K | $12.00 | $360K | 509K |
| 2025-12-18 | Todisco Joseph | Chief Executive Officer | Exercise or conversion | 30K | $4.43 | $133K | 539K |
| 2025-12-09 | Lefkowitz Steven W | Director | Sell | 40K | $11.88 | $475K | 80K |
| 2025-12-09 | Dillione Janet | Director | Sell | 34K | $12.00 | $408K | 48K |
| 2025-12-09 | Dillione Janet | Director | Exercise or conversion | 15K | $5.63 | $84K | 82K |
| 2025-12-09 | Dillione Janet | Director | Exercise or conversion | 19K | $9.55 | $181K | 67K |
| 2025-12-02 | Dillione Janet | Director | Sell | 47K | $10.00 | $467K | 48K |
| 2025-12-02 | Dillione Janet | Director | Exercise or conversion | 19K | $3.55 | $69K | 95K |
| 2025-12-02 | Dillione Janet | Director | Exercise or conversion | 15K | $4.43 | $67K | 76K |
| 2025-12-02 | Dillione Janet | Director | Exercise or conversion | 12K | $4.03 | $49K | 61K |
| 2025-11-24 | Dillione Janet | Director | Sell | 26K | $9.93 | $262K | 48K |
| 2025-11-24 | Dillione Janet | Director | Exercise or conversion | 6K | $3.55 | $20K | 75K |
| 2025-11-24 | Dillione Janet | Director | Exercise or conversion | 5K | $4.43 | $22K | 69K |
| 2025-11-24 | Dillione Janet | Director | Exercise or conversion | 8K | $4.03 | $31K | 64K |
| 2025-11-24 | Dillione Janet | Director | Exercise or conversion | 8K | $2.85 | $23K | 56K |
| 2025-11-14 | Dillione Janet | Director | Sell | 30K | $11.42 | $343K | 48K |
| 2025-10-23 | Kaplan Myron | Director | Buy | 25K | $11.02 | $276K | 201K |
| 2025-09-16 | Duncan Gregory Scott | Director | Exercise or conversion | 13K | $8.32 | $111K | 38K |
| 2025-09-12 | Todisco Joseph | Chief Executive Officer | Sell | 50K | $13.00 | $650K | 509K |
| 2025-09-12 | Todisco Joseph | Chief Executive Officer | Exercise or conversion | 50K | $3.47 | $174K | 559K |
| 2025-09-12 | DUNTON ALAN W | Director | Sell | 10K | $13.13 | $131K | 40K |
| 2025-09-12 | DUNTON ALAN W | Director | Exercise or conversion | 10K | $3.55 | $36K | 50K |
| 2025-09-11 | Hurlburt Elizabeth | Chief Operating Officer | Sell | 41K | $13.08 | $538K | 177K |
| 2025-09-11 | Hurlburt Elizabeth | Chief Operating Officer | Exercise or conversion | 41K | $1.45 | $60K | 218K |
| 2025-09-09 | Zelnick Kaufman Beth | Chief Legal Officer | Sell | 400 | $12.82 | $5K | 180K |
| 2025-09-09 | Zelnick Kaufman Beth | Chief Legal Officer | Sell | 50K | $13.41 | $665K | 181K |
| 2025-09-09 | Zelnick Kaufman Beth | Chief Legal Officer | Exercise or conversion | 50K | $3.30 | $165K | 230K |
| 2025-09-09 | Hurlburt Elizabeth | Chief Operating Officer | Sell | 13K | $13.51 | $174K | 177K |
| 2025-09-09 | Hurlburt Elizabeth | Chief Operating Officer | Exercise or conversion | 13K | $1.45 | $19K | 190K |
| 2025-08-29 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 9K | $14.83 | $132K | 180K |
| 2025-08-29 | Hurlburt Elizabeth | Chief Operating Officer | Tax withholding | 8K | $14.83 | $125K | 177K |
| 2025-08-29 | Hurlburt Elizabeth | Chief Operating Officer | Grant | 70K | $0.00 | $0 | 185K |
| 2025-08-29 | Zelnick Kaufman Beth | Chief Legal Officer | Grant | 70K | $0.00 | $0 | 189K |
| 2025-08-29 | Blum Susan | Chief Financial Officer | Grant | 70K | $0.00 | $0 | 70K |
| 2025-05-10 | Todisco Joseph | Chief Executive Officer | Tax withholding | 21K | $11.66 | $247K | 509K |
| 2025-04-02 | Lefkowitz Steven W | Director | Exercise or conversion | 20K | $4.03 | $81K | 120K |
| 2025-04-01 | Todisco Joseph | Chief Executive Officer | Exercise or conversion | 59K | $3.38 | $200K | 531K |
| 2025-01-17 | Duncan Gregory Scott | Director | Grant | 25K | $0.00 | $0 | 25K |
| 2025-01-17 | Lefkowitz Steven W | Director | Grant | 25K | $0.00 | $0 | 100K |
| 2025-01-17 | Kaplan Myron | Director | Grant | 25K | $0.00 | $0 | 176K |
| 2025-01-17 | Dillione Janet | Director | Grant | 25K | $0.00 | $0 | 78K |
| 2025-01-17 | Stewart Robert A | Director | Grant | 25K | $0.00 | $0 | 36K |
| 2025-01-17 | DUNTON ALAN W | Director | Grant | 25K | $0.00 | $0 | 40K |
| 2025-01-17 | Todisco Joseph | Chief Executive Officer | Tax withholding | 24K | $12.17 | $292K | 472K |
| 2025-01-17 | Todisco Joseph | Chief Executive Officer | Grant | 188K | $0.00 | $0 | 496K |
| 2025-01-10 | Hurlburt Elizabeth | EVP | Tax withholding | 6K | $11.19 | $65K | 116K |
| 2025-01-10 | Mistry Erin | EVP, Chief Commercial Officer | Tax withholding | 6K | $11.19 | $64K | 101K |
| 2025-01-10 | Todisco Joseph | Chief Executive Officer | Tax withholding | 18K | $11.19 | $200K | 308K |
| 2025-01-10 | David Matthew T | Chief Financial Officer | Tax withholding | 7K | $11.19 | $73K | 95K |
| 2025-01-02 | Zelnick Kaufman Beth | Chief Legal Officer | Grant | 88K | $0.00 | $0 | 131K |
| 2025-01-02 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 12K | $8.22 | $97K | 120K |
| 2025-01-02 | David Matthew T | Chief Financial Officer | Tax withholding | 9K | $8.22 | $71K | 102K |
| 2025-01-02 | David Matthew T | Chief Financial Officer | Grant | 63K | $0.00 | $0 | 110K |
| 2025-01-02 | Hurlburt Elizabeth | EVP | Grant | 88K | $0.00 | $0 | 133K |
| 2025-01-02 | Hurlburt Elizabeth | EVP | Tax withholding | 11K | $8.22 | $94K | 122K |
| 2025-01-02 | Mistry Erin | EVP, Chief Commercial Officer | Tax withholding | 8K | $8.22 | $64K | 107K |
| 2025-01-02 | Mistry Erin | EVP, Chief Commercial Officer | Grant | 63K | $0.00 | $0 | 115K |
| 2024-12-12 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 6K | $8.77 | $53K | 56K |
| 2024-12-12 | Zelnick Kaufman Beth | Chief Legal Officer | Exercise or conversion | 13K | price not stated in the filing | not stated | 63K |
| 2024-12-12 | Zelnick Kaufman Beth | Chief Legal Officer | Tax withholding | 6K | $8.77 | $53K | 44K |
| 2024-11-14 | Hurlburt Elizabeth | EVP | Exercise or conversion | 3 | $1.45 | $4 | 45K |
| 2024-11-14 | Hurlburt Elizabeth | EVP | Exercise or conversion | 8K | $8.30 | $68K | 54K |
| 2024-11-14 | Hurlburt Elizabeth | EVP | Exercise or conversion | 10K | $5.63 | $56K | 63K |
| 2024-11-14 | Hurlburt Elizabeth | EVP | Exercise or conversion | 34K | $4.08 | $141K | 98K |
| 2024-11-14 | Hurlburt Elizabeth | EVP | Exercise or conversion | 63K | $4.43 | $277K | 160K |
| 2024-11-14 | Hurlburt Elizabeth | EVP | Exercise or conversion | 25K | $3.47 | $87K | 185K |
| 2024-11-14 | Hurlburt Elizabeth | EVP | Sell | 140K | $11.18 | $1.6M | 45K |
| 2024-10-31 | Mistry Erin | EVP, Chief Commercial Officer | Buy | 2K | $9.99 | $15K | 52K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON9 Form 144 notices on file for CRMD worth $2.9M at the prices reported; 0 in the last 90 days worth $0. Latest: Janet Dillione filed on 2026-01-21 to sell 10,000 shares ($69K) from 2026-01-21.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-01-21 | Janet DillioneDirector | 10K | $69K | 0.013% | 2026-01-21 | Merrill Lynch |
| 2025-12-30 | Alan DuntonDirector | 20K | $259K | 0.025% | 2025-12-30 | Merrill Lynch |
| 2025-12-18 | Joseph TodiscoOfficer | 30K | $359K | 0.038% | 2025-12-18 | Merrill Lynch |
| 2025-12-09 | Lefkowitz Steven WDirector | 40K | $450K | 0.051% | 2025-12-09 | Fidelity Brokerage Services LLC |
| 2025-12-09 | Janet DillioneBOD | 34K | $408K | 0.043% | 2025-12-09 | Merrill Lynch |
| 2025-11-24 | Janet DillioneDirector | 73K | $728K | 0.093% | 2025-11-24 | Merrill Lynch |
| 2025-11-14 | Dillione JanetDirector | 30K | $328K | 0.038% | 2025-11-14 | Commonwealth Financial Network |
| 2025-11-10 | Erin MistryFormer Officer | 14K | $149K | 0.018% | 2025-11-10 | Merrill Lynch |
| 2025-11-06 | Erin MistryFormer Officer | 14K | $153K | 0.019% | 2025-11-06 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of CRMD in their latest filing, all on Schedule 13G (passive). The largest reported stake is Deep Track Biotechnology Master Fund, Ltd. at 7.9% of the class (6,274,076 shares), filed 2026-05-15 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-06-12 | 13G/Ano. 5 | SHAIBATALHAMD AYMEN ABDALKADERindividual | 4.6M | 5.9% | 2026-06-11 |
| 2026-05-15 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 6.3M | 7.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 6.3M | 7.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | David Kroinparent holding company, individual | 6.3M | 7.9% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding CRMD at their latest 13F. JSON4 of the 30 tracked managers held CRMD at their latest 13F, $3.3M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $1.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 172K | $1.3M | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 151K | $1.2M | 0.00% | -83K |
| Citadel Advisors | 2026-06-30 | 57K | $444K | 0.00% | -186K |
| Two Sigma Investments | 2026-06-30 | 41K | $321K | 0.00% | +20K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) CorMedix reported revenue of $101.9M, up 156.5% from the same quarter a year earlier, and net income of $26.0M (0.29 diluted EPS). In FY 2025 it generated $175.0M of operating cash flow.
- Cash
- $256.7M
- Equity
- $460.8M
- Total assets
- $904.1M
- Shares outstanding
- 77,944,324
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $101.9M | $26.0M | 25.5% | 0.29 |
| Q1 FY 2026 | 2026-03-31 | $127.4M | $38.6M | 30.3% | 0.43 |
| Q4 FY 2025derived | 2025-12-31 | $128.6M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $104.3M | $108.6M | 104.1% | 1.26 |
| Q2 FY 2025 | 2025-06-30 | $39.7M | $19.8M | 49.9% | 0.28 |
| Q1 FY 2025 | 2025-03-31 | $39.1M | $20.6M | 52.8% | 0.30 |
| Q4 FY 2024derived | 2024-12-31 | n/a | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $11.5M | -$2.8M | -24.2% | -0.05 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $311.7M | $163.1M | $175.0M | $2.3M | n/a | n/a |
| FY 2024 | 2024-12-31 | $43.5M | -$17.9M | -$50.6M | $116K | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$46.3M | -$38.4M | $327K | n/a | n/a |
| FY 2022 | 2022-12-31 | $65K | -$29.7M | -$24.4M | $219K | n/a | n/a |
| FY 2021 | 2021-12-31 | $191K | -$28.2M | -$21.2M | $1.4M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-10 from the cover page.
What this page is
CorMedix in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows CorMedix (CRMD), SEC CIK 1410098, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-18.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-01-21.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-06-12.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-11-02.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-18.JSON and CSV
- Company record
- EDGAR filing index for CIK 1410098Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of CRMD is sold short?
14,665,697 shares were held short at the 2026-10-15 settlement, 12.7 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CRMD's daily short volume?
On 2026-11-03, 638,786 of the 912,490 CRMD shares reported to FINRA were sold short, 70.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CRMD have fails to deliver?
The SEC's latest file shows 3,210 CRMD shares failed to deliver at settlement 2026-09-18. Fails are reported per settlement date and published twice a month with a lag.
Are CRMD insiders buying or selling?
No open-market insider trades were reported for CRMD in the last 90 days. The most recent filings are listed below. Latest filing: Dillione Janet (Director) on 2026-09-18.
Have CRMD insiders filed to sell?
9 Form 144 notices on file for CRMD worth $2.9M at the prices reported; 0 in the last 90 days worth $0. Latest: Janet Dillione filed on 2026-01-21 to sell 10,000 shares ($69K) from 2026-01-21.
Who owns 5% or more of CRMD?
4 holders report 5% or more of CRMD in their latest filing, all on Schedule 13G (passive). The largest reported stake is Deep Track Biotechnology Master Fund, Ltd. at 7.9% of the class (6,274,076 shares), filed 2026-05-15 for an event on 2026-03-31.
What did CRMD report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) CorMedix reported revenue of $101.9M, up 156.5% from the same quarter a year earlier, and net income of $26.0M (0.29 diluted EPS). In FY 2025 it generated $175.0M of operating cash flow.
Which tracked 13F managers own CRMD?
4 of the 30 tracked 13F managers held CRMD shares at their latest filing, $3.3M in all. The largest: D. E. Shaw & Co. (172K shares, $1.3M), Cliff Asness's AQR Capital Management (151K shares, $1.2M), Ken Griffin's Citadel Advisors (57K shares, $444K), Two Sigma Investments (41K shares, $321K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.